Japan’s Esai Tender Offer For MGI Pharma Of U.S. Passes 96 Percent

Eisai says it has completed its tender offer for U.S. drug maker MGI Pharma after receiving an interest in selling from 96.1 percent of shareholders at the Eisai asking price. The Japanese firm said it extended its offer to the remaining shareholders through Jan. 25 in an attempt to own 100 percent. If the purchase is completed at a cost expected to reach $3.9 billion, Eisai plans to remove MGI Pharma from the U.S. stock market. (Click here for more - may be a subscription